Cargando…

Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging

BACKGROUND: Brain change can occur in primary biliary cholangitis (PBC), potentially as a result of cholestatic and/or inflammatory processes. This change is linked to systemic symptoms of fatigue and cognitive impairment. AIM: To identify whether brain change occurs early in PBC. If the change deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grover, V. P. B., Southern, L., Dyson, J. K., Kim, J. U., Crossey, M. M. E., Wylezinska‐Arridge, M., Patel, N., Fitzpatrick, J. A., Bak‐Bol, A., Waldman, A. D., Alexander, G. J., Mells, G. F., Chapman, R. W, Jones, D. E. J., Taylor‐Robinson, S. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Primary Biliary Cholangitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082539/ https://www.ncbi.nlm.nih.gov/pubmed/27604637 http://dx.doi.org/10.1111/apt.13797

Ejemplares similares

The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis
por: Dyson, J. K, et al.
Publicado: (2016)

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: de Veer, Rozanne C., et al.
Publicado: (2022)

Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease
por: Wang, W, et al.
Publicado: (2015)

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study
por: Papastergiou, V, et al.
Publicado: (2013)

Primary biliary cholangitis: pathogenic mechanisms
por: Prieto, Jesús, et al.
Publicado: (2021)

Anti‐glycoprotein 2 (anti‐GP2) IgA and anti‐neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3‐ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis
por: Wunsch, Ewa, et al.
Publicado: (2020)

A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy
por: Grover, Vijay P. B., et al.
Publicado: (2016)

Unique patterns of glycosylation in immunoglobulin subclass G4‐related disease and primary sclerosing cholangitis
por: Culver, Emma L, et al.
Publicado: (2018)

Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis
por: Ludwig, Daniel R., et al.
Publicado: (2022)

Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study
por: Hoilat, Gilles Jadd, et al.
Publicado: (2021)

Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
por: Fasullo, Matthew, et al.
Publicado: (2022)

Immunoglobulin G4(+) B‐cell receptor clones distinguish immunoglobulin G 4‐related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies
por: Doorenspleet, Marieke E., et al.
Publicado: (2016)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: a single tertiary referral centre experience and systematic review
por: On, Wei, et al.
Publicado: (2022)

Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis
por: Boonstra, Kirsten, et al.
Publicado: (2014)

Electrostatic Modifications of the Human Leukocyte Antigen-DR P9 Peptide-Binding Pocket and Susceptibility to Primary Sclerosing Cholangitis
por: Hov, Johannes R, et al.
Publicado: (2011)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
por: Molinaro, Antonio, et al.
Publicado: (2017)

Clinical application of the GLOBE and United Kingdom‐primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis
por: Carbone, Marco, et al.
Publicado: (2018)

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
por: Zhou, Mei, et al.
Publicado: (2016)

Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?
por: Wetten, Aaron, et al.
Publicado: (2022)

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
por: Hirschfield, Gideon M., et al.
Publicado: (2023)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study
por: Jones, David E.J., et al.
Publicado: (2022)

‘Biliary Atresia: Back to the Future’ 특별호 발간에 부쳐
Publicado: (2022)

Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells
por: Mulcahy, Victoria, et al.
Publicado: (2023)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

The National Audit of Primary Biliary Cholangitis (PBC) in the United Kingdom: Defining the Audit Dataset and Data Collection System
por: Burke, Laura, et al.
Publicado: (2022)

Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis
por: Dyson, Jessica Katharine, et al.
Publicado: (2020)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Interventional treatment of biliodigestive anastomosis leaks with a modified percutaneous transhepatic cholangiodrainage
por: Lopez Benitez, Ruben, et al.
Publicado: (2022)

Cost-effectiveness analysis of antibiotic prophylaxis versus no antibiotic prophylaxis for acute cholecystectomy
por: Satheeskaran, Maya, et al.
Publicado: (2023)

Early Molecular Stratification of High-risk Primary Biliary Cholangitis
por: Hardie, Claire, et al.
Publicado: (2016)

Cholangitis Due to Candidiasis of the Extra-Hepatic Biliary Tract
por: Wig, J. D., et al.
Publicado: (1998)

Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel
por: Pate, Jennifer, et al.
Publicado: (2019)

Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells
por: Jeney, A., et al.
Publicado: (2016)

Differential Diagnosis of Immunoglobulin G4-associated Cholangitis From Cholangiocarcinoma
por: Du, Shunda, et al.
Publicado: (2016)

The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia
por: Mohanty, Sujit K., et al.
Publicado: (2017)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
por: Montali, Lorenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_941pbrrv42sn8e94l4ul44f3re